Primary dyslipidemia and cardiometabolic risk: potential of pitavastatin

. The review is de­voted to the most important aspects of primary mixed dyslipidemia treatment in patients at high risk with concomitant metabolic comorbidities. Evidences for novel modern approaches regarding primary prevention of cardiovascular events among dyslipidemic patients are considered. Th...

Full description

Saved in:
Bibliographic Details
Published inMedychni perspektyvy Vol. 20; no. 2; pp. 54 - 62
Main Authors Berezin, A E, Sheychenko, T V, Berezina, T A, Vishnevaya, N V, Kovalenko, N V, Kulik, Z I, Мoiseenko, I А
Format Journal Article
LanguageEnglish
Russian
Ukrainian
Published Dnipropetrovsk Dnipro State Medical University 01.01.2015
Subjects
cardiometabolic risk
dyslipidemia
Health risk assessment
Metabolic disorders
Metabolic syndrome
pitavastatin
Statins
Online AccessGet full text

Cover

More Information
Summary:. The review is de­voted to the most important aspects of primary mixed dyslipidemia treatment in patients at high risk with concomitant metabolic comorbidities. Evidences for novel modern approaches regarding primary prevention of cardiovascular events among dyslipidemic patients are considered. The potential role of lipid-lowering treatment with statins and their role in reducing the cardiovascular risk are discussed. Information about modern methods of minimization of residual cardiovascular risk using a combined lipid-lowering strategies and new representatives of the statins are provided.Ithasbeendiscussedvariousstrategiesofstatinadministeringtopatientswithdyslipidemiaof different agewith exiting comorbidities, such as diabetes mellitus, obesity, metabolic syndrome. Objective findingsand treatment approaches obtainedfromthe patientwithobesity, metabolic syndrome, and asymptomatic atherosclerosis are provided. The role of pitavastatin in primary prevention program of cardiovascular events is discussed.
ISSN:2307-0404
2307-0404
DOI:10.26641/2307-0404.2015.2.45652